News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MGI PHARMA, INC. (MOGN): Dacogen(R) (Decitabine) for Injection Data Presented at the American Society of Hematology 49th Annual Meeting and Exposition



12/11/2007 2:14:23 PM

ATLANTA--(BUSINESS WIRE)--MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today provided a summary of the DacogenĀ® (decitabine) for Injection presentations made during the American Society of Hematology (ASH) 49th Annual Meeting and Exposition. Dacogen was the subject of five oral presentations, 11 poster presentations, and four publications. A survival analysis of the five-day outpatient regimen of Dacogen in patients with myelodysplastic syndromes (MDS) and preliminary results from a multicenter, phase 2 study evaluating the five-day regimen of Dacogen in patients with de novo or secondary MDS were among the data presented. Data from a phase 2 trial evaluating Dacogen in older patients with acute myelogenous leukemia (AML) were also presented at the conference.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES